Press Releases Vaccinex, Inc.

Equities

VCNX

US9186403013

Market Closed - Nasdaq Other stock markets 16:30:00 2024-06-25 EDT			5-day change	1st Jan Change
5.79 ^USD	-4.62%		-5.55%	-37.79%

06-06	Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer?s Disease	CI
05-16	Earnings Flash (VCNX) VACCINEX Reports Q1 Revenue $104,000	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's disease	06-07	AQ
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease	06-06	AQ
Vaccinex : ASCO Conference Presentation	06-01	PU
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update	05-15	AQ
VACCINEXPAR : 12th Alzheimer’s & Parkinson’s Drug Development Summit Presentation	04-26	PU
Vaccinex Reports 2023 Financial Results and Provides Corporate Update	04-02	AQ
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	03-27	AQ
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology	02-21	AQ
Vaccinex, Inc. Announces Reverse Stock Split	02-15	AQ
Vaccinex Announces Pricing of $3.7 Million PIPE Financing	02-07	AQ
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule	12-04	AQ
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update	11-13	AQ
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting	23-10-31	AQ
Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease: clinical proof of concept in Phase 2 HD study supports clinical development in and ongoing Phase 1/2 AD study	23-10-26	PU
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases	23-10-26	AQ
Keystone Symposium: B cells and TLS_POSTER	23-10-04	PU
Vaccinex Announces Pricing of $9.6 Million Public Offering	23-09-28	AQ
Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration	23-09-28	AQ
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application	23-09-27	GL
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application	23-09-27	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Vaccinex, Inc.

Equities

VCNX

US9186403013

Press Releases

Filters